Viewing nowCombinationJanudim Extended-release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.

MFDS item code 202300600 · Approved 2023.02.17 · Insurance code 643705440
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to enhance blood sugar control in patients with type 2 diabetes in conjunction with diet and exercise. Specifically, Sitagliptin and Metformin work together to effectively lower blood sugar levels, serving as an important therapeutic agent to assist patients in managing their blood sugar better.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with food once daily, preferably in the evening, and increase the dose gradually. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at their current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined taking into account the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication contains both Sitagliptin and Metformin, helping to control blood sugar. Firstly, it may cause serious allergic reactions in some patients, so if symptoms such as rash, hives, or difficulty breathing occur, the medication should be discontinued immediately, and a doctor should be consulted. Also, acute pancreatitis, an inflammation of the pancreas may occur, so symptoms such as abdominal pain, nausea, and vomiting should be closely monitored and reported to a doctor. The Metformin component included in this medication can rarely lead to a serious metabolic disorder known as lactic acidosis, which may present with symptoms such as muscle pain, weakness, difficulty breathing, and abdominal pain; these symptoms should prompt immediate notification to healthcare staff. Patients with poor kidney function, severe infections, or dehydration, and those with acute myocardial infarction or heart failure should not use this medication as it may pose risks. In addition, the use of iodine contrast agents before and after scans may worsen kidney function and pose a risk of lactic acidosis, so use of this drug should be temporarily halted, resuming only after confirming normal kidney function post-scan. Women who are pregnant or breastfeeding are advised against using this medication, and safety has not been established for children under the age of 18. This medication may increase the risk of hypoglycemia due to irregular meals, intense exercise, or interactions with other medications, thus careful monitoring of blood sugar changes is necessary. Furthermore, long-term use may lower vitamin B12 levels, so regular blood tests are recommended, and alcohol intake should be avoided due to the risk of lactic acidosis. Patients scheduled for surgery should discontinue this medication 48 hours before surgery and resume only after normal oral intake and confirmation of kidney function. Finally, regular monitoring of blood sugar, kidney function, and hematological tests should be conducted while taking this medication, and any unusual symptoms should be promptly discussed with healthcare staff.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is essential to maintain a storage temperature between 1 and 30 degrees Celsius. This helps to preserve the effectiveness and safety of the medication for an extended period.
Bright green oval-shaped extended-release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.